Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB10 in Neovascular Age-related Macular Degeneration (nAMD)
NCT07406438Phase 1Not yet recruiting
- Sponsor
- Kexing Biopharm
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB10 in neovascular age-related macular degeneration (NVAMD) (8 arms), sponsored by Kexing Biopharm. Primary endpoints: Incidence and severity of ocular adverse events at 12 weeks, Incidence and severity of non-ocular adverse events at 12 weeks and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
GB10
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07406438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406438.